RAPTRAPT Therapeutics, Inc.

$959M

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+30.7% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$17M-1355.2% margin

Net Income

-$17M-1351.4% margin

EPS (Diluted)

$-5.32

QoQ Revenue Growth

-6.1%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$106M

Total Liabilities

$14M

Stockholders' Equity

$92M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$935,000	+30.7%
Gross Profit	$1M	$935,000	+30.7%
Operating Income	-$17M	-$13M	-27.0%
Net Income	-$17M	-$13M	-25.7%

RAPT Q1 2021 Earnings — RAPT Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena